[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
2. Kurtkaya-Yapícíer O, Scheithauer BW, Dedrick DJ, Wascher TM: Primary epithelioid sarcoma of the dura: case report. Neurosurgery; 2002 Jan;50(1):198-202; discussion 202-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epithelioid sarcoma of the dura: case report.
  • CLINICAL PRESENTATION: We present the case of an 18-year-old woman with a unique dural sarcoma that arose in the right frontotemporal region.
  • As visualized on magnetic resonance imaging studies, the 4.5-cm tumor focally traversed the cranium to penetrate the galea, the temporal muscle, and subcutaneous tissue.
  • INTERVENTION: Despite gross total removal and postoperative radiotherapy (59 Gy), a large recurrence was noted 5 months after surgery.
  • CONCLUSION: With the inclusion of epithelioid sarcoma, the spectrum of central nervous system sarcomas continues to expand.
  • [MeSH-major] Dura Mater / surgery. Meningeal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Microscopy, Electron. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11852861.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Alvarez M: Intracerebral granulocytic sarcoma. J Neurosci Nurs; 2007 Oct;39(5):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracerebral granulocytic sarcoma.
  • Leukemia involvement of the central nervous system most commonly presents as meningeal leukemia; intracerebral granulocytic sarcoma (IGS) is rare.
  • Magnetic resonance imaging with and without gadolinium is the imaging of choice to evaluate the tumor; however, tissue biopsy is essential for definitive diagnosis.
  • Treatment usually involves radiation followed by chemotherapy, depending on the previous systemic treatment.
  • Because medical literature about IGS is scarce, optimal treatment is unclear.
  • Nurses play a vital role in helping patients and families understand the disease process, the treatments involved, and the necessary adjustments, such as performing mundane activities of daily living, especially when neurocognitive impairments are present.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Blood-Brain Barrier. Cerebral Hemorrhage / etiology. Cognition Disorders / etiology. Headache / etiology. Humans. Incidence. Infection / etiology. Leukemic Infiltration. Magnetic Resonance Imaging. Male. Middle Aged. Nurse's Role / psychology. Patient Education as Topic. Prognosis. Radiotherapy, Adjuvant. Rare Diseases. Tomography, X-Ray Computed. Tumor Lysis Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966297.001).
  • [ISSN] 0888-0395
  • [Journal-full-title] The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • [ISO-abbreviation] J Neurosci Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Drabko K, Choma M, Zaucha-Prazmo A, Wójcik B, Gorczyńska E, Kałwak K, Turkiewicz D, Słociak M, Ussowicz M, Dyla A, Chybicka A, Styczyński J, Debski R, Wysocki M, Goździk J, Ratajczak M, Kowalczyk JR: [Megachemotherapy and autologous hematopoietic stem cell transplantation in children with solid tumours excluding neuroblastoma--experience of Polish paediatric centres]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 25 children were treated for Ewing Sarcoma, 13 for rhabdomyosarcoma embryonale (RMS), 7 for germinal tumours, 6 for medulloblastoma, 4 for PNET, 4 for Wilm's tumours, 2 for glioblastoma and single patients with mesenchymoma, astrocytoma, ependymoma, angioblastoma, carcinoma ovarian and carcinoma embryonale glutei.
  • In 29 children MCH was introduced in first complete remission, in 14 the procedure was performed in second or subsequent remission and 24 patients did not achieve remission before megachemotherapy was started.
  • 23 out of 29 (79%) patients were transplanted in first complete remission and median observation time in that group is 29 months (range 2-74 months).
  • 39 patients relapsed at a median time 11 months after MCT and 37 of them subsequently died of disease at a median time of 16 months.
  • It is a safe procedure especially when performed in remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Neoplasms / drug therapy. Neoplasms / surgery
  • [MeSH-minor] Academic Medical Centers. Adolescent. Antineoplastic Agents, Alkylating / administration & dosage. Bone Neoplasms / drug therapy. Bone Neoplasms / surgery. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Ependymoma / drug therapy. Ependymoma / surgery. Female. Glioblastoma / drug therapy. Glioblastoma / surgery. Glioma / drug therapy. Glioma / surgery. Humans. Infant. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / surgery. Meningioma / drug therapy. Meningioma / surgery. Neoplasm Staging. Oncology Service, Hospital. Poland. Remission Induction. Retrospective Studies. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Transplantation, Autologous. Treatment Outcome


5. El Khorassani M, Benbrahim F, Hessissen L, Khattab M, Msefer F: [Intracerebral granulocytic sarcoma. A case report]. Neurochirurgie; 2003 May;49(2-3 Pt 1):119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebral granulocytic sarcoma. A case report].
  • Granulocytic sarcoma is a tumor composed of proliferating myeloblastic cells, generally found in the orbit.
  • After 21 months of complete remission, he developed headache and facial palsy.
  • A new medullar and cerebro-meningeal remission was obtained with chemotherapy and radiotherapy.
  • CSF and the bone marrow studies can help avoid stereotaxic biopsy can be avoided in this type of tumor
  • [MeSH-major] Brain Stem Neoplasms / radiography. Leukemia, Myeloid, Acute / complications. Sarcoma, Myeloid / radiography
  • [MeSH-minor] Bone Marrow / pathology. Child. Combined Modality Therapy. Contrast Media. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12746729.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


6. Navarro R, Laguna A, de Torres C, Cigudosa JC, Suñol M, Cruz O, Mora J: Primary Ewing sarcoma of the tentorium presenting with intracranial hemorrhage in a child. J Neurosurg; 2007 Nov;107(5 Suppl):411-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing sarcoma of the tentorium presenting with intracranial hemorrhage in a child.
  • The occurrence of primitive central nervous system lesions in the Ewing sarcoma family of tumors (ESFT) not related to bone or metastatic disease is a rare condition.
  • The authors report on a child who presented with intracranial bleeding secondary to a nonmetastatic tentorial ESFT confirmed by detection of the fusion gene EWS-ERG.
  • A detailed review of the literature reveals that most primary intracranial ESFT had a meningeal attachment, and that almost half of them presented at diagnosis with hemorrhage.
  • Distinguishing between ESFT and other intracranial neoplasms is essential because the treatment and prognosis differ remarkably from that of other tumors, namely central primitive neuroectodermal tumors (PNETs).
  • Whereas adjuvant treatment for ESFT consists of local or regional radiotherapy and chemotherapy containing alkylating agents, central PNETs are generally treated with whole neuraxis radiation and platinum-based chemotherapy.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / surgery. Intracranial Hemorrhages / etiology. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / surgery

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459906.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


7. Furuno Y, Nishimura S, Kamiyama H, Numagami Y, Saito A, Kaimori M, Nishijima M: Intracranial peripheral-type primitive neuroectodermal tumor. Neurol Med Chir (Tokyo); 2008 Feb;48(2):72-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial peripheral-type primitive neuroectodermal tumor.
  • Digital subtraction angiography of the external carotid artery revealed sunburst appearance corresponding to the tumor, which was fed by the right middle meningeal artery.
  • His headache worsened and computed tomography revealed enlargement of the tumor and intracystic hemorrhage, so emergent operation was performed.
  • The histological diagnosis was peripheral-type primitive neuroectodermal tumor (pPNET).
  • Following surgery, radiation therapy and chemotherapy were given.
  • Ewing's sarcoma and pPNET form a family of small round cell tumors arising in the bone or soft tissue.
  • MIC-2 is a useful marker in the differential diagnosis.
  • [MeSH-minor] Adolescent. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Diagnosis, Differential. Frontal Lobe / pathology. Headache / etiology. Headache / pathology. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Temporal Lobe / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18296876.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Ki-67 Antigen
  • [Number-of-references] 20
  •  go-up   go-down


9. Lopez-Gonzalez MA, Sotelo J: Brain tumors in Mexico: characteristics and prognosis of glioblastoma. Surg Neurol; 2000 Feb;53(2):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean survival for glioblastoma was 16 months and the longest mean survival was obtained in patients with radical neurosurgical resection plus radiotherapy and chemotherapy.
  • Factors that showed prognostic significance were age, therapeutic approach, tumor size, and pre- and postoperative clinical status (p < 0.05).
  • Mean survival for glioblastoma was similar to other reports; in these patients, the overall therapeutic response is still far from satisfactory.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy
  • [MeSH-minor] Adenoma / diagnosis. Female. Glioblastoma / diagnosis. Humans. Karnofsky Performance Status. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Mexico / epidemiology. Middle Aged. Pituitary Neoplasms / diagnosis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Sarcoma / diagnosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10713194.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Binder C, Tiemann M, Haase D, Humpe A, Kneba M: Isolated meningeal chloroma (granulocytic sarcoma)--a case report and review of the literature. Ann Hematol; 2000 Aug;79(8):459-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated meningeal chloroma (granulocytic sarcoma)--a case report and review of the literature.
  • There are still no conclusive treatment strategies for this entity; however, early antileukemic chemotherapy seems to lower the probability of developing systemic disease and prolong survival.
  • We report on a patient with isolated meningeal chloroma, primarily misdiagnosed as a high-grade Non-Hodgkin's lymphoma.
  • Two cycles of antileukemic induction chemotherapy were administered, followed by local irradiation and intensified consolidation therapy with autologous stem cell transplantation.
  • [MeSH-major] Leukemia, Myeloid / therapy. Meningeal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Drug Therapy. Hematopoietic Stem Cell Transplantation. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985368.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 40
  •  go-up   go-down


11. Utsunomiya A, Uenohara H, Suzuki S, Shimosaka S, Numagami Y, Nishimura S, Nishino A, Suzuki H, Sakurai Y: [A case of peripheral-type primitive neuroectodermal tumor arising in the dura mater at the frontal base]. No To Shinkei; 2004 Mar;56(3):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peripheral-type primitive neuroectodermal tumor arising in the dura mater at the frontal base].
  • Angiography showed the tumor was fed by anterior meningeal arteries.
  • The tumor was histologically confirmed to be peripheral-type primitive neuroectodermal tumor(pPNET).
  • Following surgery, he underwent whole brain, whole spine and local radiation therapy(30 Gy in total respectively) and received two 5-day cycles of chemotherapy, consisting of intravenous administration of cisplatin 20 mg/m2/day, etoposide 60 mg/m2/day and IFOS 900 mg/m2/day.
  • After these therapies, follow-up radiological examination showed there was no recurrence of the tumor for 24 months.
  • Ewing sarcoma and pPNET(ES/pPNET) is the designation given to a family of small round cell tumor arising in bone or soft tissues.
  • It is necessary that intracranial PNETs are divided into two types of PNETs because of different prognosis between these tumors.
  • MIC-2 is a specific marker for pPNET/ES family and is useful in the differential diagnosis of these two types of tumors.
  • [MeSH-major] Dura Mater. Meningeal Neoplasms / diagnosis. Neuroectodermal Tumors, Primitive, Peripheral / diagnosis
  • [MeSH-minor] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / analysis. Chemotherapy, Adjuvant. Child. Diagnosis, Differential. Humans. Magnetic Resonance Angiography. Male. Radiotherapy, Adjuvant. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15112448.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


12. Ahn JY, Choi EW, Kang SH, Kim YR: Isolated meningeal chloroma (granulocytic sarcoma) in a child with acute lymphoblastic leukemia mimicking a falx meningioma. Childs Nerv Syst; 2002 Apr;18(3-4):153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated meningeal chloroma (granulocytic sarcoma) in a child with acute lymphoblastic leukemia mimicking a falx meningioma.
  • Granulocytic sarcoma occurs primarily in patients with acute myelogenous leukemia, but can also arise in patients with other myeloproliferative disorders, though rarely in patients with acute lymphoblastic leukemia (ALL).
  • When dural-based, granulocytic sarcoma may be indistinguishable from meningioma radiologically.
  • CASE HISTORY: We now describe one patient affected by ALL with isolated granulocytic sarcoma mimicking meningioma as initial CNS relapses.
  • A 12-year-old girl who had been diagnosed with ALL and undergone chemotherapy presented with generalized tonic-clonic seizure while in complete remission.
  • The patient was developed speech disturbance 6 days later.
  • The pathological diagnosis was acute lymphoblastic leukemia.
  • Early detection and antileukemic treatment of granulocytic sarcoma are necessary and important for a favorable prognosis.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Second Primary / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981624.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Balleari E, Panarello S, Capello E, Grosso M, Passalia C, Pitto P, Raggi F, Roccatagliata L, Cabiddu F, Ghio R: Granulocytic sarcoma: an unusual cause of spinal cord compression. Int J Clin Oncol; 2007 Jun;12(3):234-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma: an unusual cause of spinal cord compression.
  • At subsequent clinical workup, a diagnosis of granulocytic sarcoma with meningeal involvement was made.
  • Unfortunately, despite receiving intensive care, shortly after induction chemotherapy, the patient died of acute pneumonia followed by acute respiratory distress syndrome.
  • [MeSH-major] Sarcoma, Myeloid / pathology. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] J Med Liban. 2003 Apr-Jun;51(2):117-9 [15298165.001]
  • [Cites] Eur J Pediatr. 2005 Oct;164(10 ):616-20 [16012854.001]
  • [Cites] Neurol India. 2005 Jun;53(2):221-3 [16010065.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1753-60 [14692530.001]
  • [Cites] Cancer. 2000 Dec 25;90(6):364-72 [11156520.001]
  • [Cites] Leuk Lymphoma. 2003 Sep;44(9):1619-21 [14565668.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • (PMID = 17566850.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


14. Passarin MG, Vattemi E, Musso AM, Romito S, Moretto G, Ghimenton C, Iuzzolino P, Doglioni C, Pedersini R: Intracranial granulocytic sarcoma after chemotherapy for pineal germinoma and testicular cancer. J Clin Oncol; 2008 Sep 20;26(27):4507-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial granulocytic sarcoma after chemotherapy for pineal germinoma and testicular cancer.
  • [MeSH-major] Brain Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / therapy. Pinealoma / therapy. Sarcoma, Myeloid / diagnosis. Spinal Cord Neoplasms / secondary. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Germinoma / diagnosis. Germinoma / therapy. Humans. Male. Neoplasm Staging. Orchiectomy. Remission Induction


15. Sasayama T, Nishihara M, Tanaka K, Mizukawa K, Ehara K, Kanomata N, Kohmura E: Two metachronous tumors induced by radiation therapy: case report and review of the literature. J Neurooncol; 2008 Jul;88(3):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two metachronous tumors induced by radiation therapy: case report and review of the literature.
  • Various radiation-induced tumors, including meningioma, glioma, and sarcoma, have been reported; however, metachronous intracranial double tumors induced by radiation therapy are extremely rare.
  • A 1-year-old boy had undergone tumor removal and craniospinal radiation therapy (30 Gy) for cerebellar medulloblastoma.
  • At 24 years old, parasagittal meningioma developed in the left parietal region and was totally removed.
  • As the patient had previously had craniospinal irradiation, no additional radiation therapy was delivered.
  • He underwent chemotherapy with temozolomide and the disease is now stable.
  • Since both secondary tumors were located within the area of previous radiation and the patient did not have any genetic disease predisposing him to tumors, radiation therapy was considered to be responsible for their tumorigenesis.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1002-13 [15200115.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):393-6 [9007876.001]
  • [Cites] Radiat Oncol. 2007 Jan 11;2:5 [17217530.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):143-6 [10729825.001]
  • [Cites] Childs Nerv Syst. 2006 Sep;22(9):1201-7 [16570196.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4091-5 [8508374.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Neurol Res. 2007 Oct;29(7):723-6 [17553214.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):763-70 [9810442.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20 [10901233.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):223-8 [10096432.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • [Cites] Neurosurgery. 1996 May;38(5):915-24; discussion 924-5 [8727816.001]
  • (PMID = 18373066.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tamiya T, Ono Y, Daido S, Tokunaga K, Hamazaki S, Kawai A, Ohmoto T: Primary Ewing's sarcoma/peripheral primitive neuroectodermal tumor at the vertex of the skull with elevated serum carcinoembryonic antigen: case report. J Neurooncol; 2001 Apr;52(2):173-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing's sarcoma/peripheral primitive neuroectodermal tumor at the vertex of the skull with elevated serum carcinoembryonic antigen: case report.
  • A primary Ewing's sarcoma arising in the skull is relatively rare.
  • Although a small number of case reports noted elevated carcinoembryonic antigen (CEA) in patients with primary central nervous system (CNS) neoplasms, there is no report of Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET) with elevated serum levels of CEA.
  • The patient initially underwent an embolization of the bilateral middle meningeal arteries with Gelfoam particles.
  • On histopathological and molecular genetic examination, the tumor was diagnosed as a Ewing's sarcoma/peripheral PNET.
  • The serum level of CEA was normalized at 0.83 ng/ml after the tumor was removed and the boy underwent radiotherapy and 3 courses of chemotherapy.
  • This is the first reported case of a primary Ewing's sarcoma/peripheral PNET at the vertex of the skull with elevated serum CEA.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Neuroectodermal Tumors, Primitive / pathology. Sarcoma, Ewing / pathology. Skull Neoplasms / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1996 Jul;85(1):163-9 [8683268.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):67-81 [10202129.001]
  • [Cites] J Neurosurg. 1980 Sep;53(3):355-60 [7420150.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):62-8; discussion 68-9 [10626936.001]
  • [Cites] Hum Pathol. 1996 Apr;27(4):408-16 [8617485.001]
  • [Cites] Am J Surg Pathol. 1993 Jan;17(1):1-13 [8383465.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):129-32 [1984492.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):141-4 [10413168.001]
  • [Cites] J Exp Med. 1965 Mar 1;121:439-62 [14270243.001]
  • [Cites] J Neurosurg. 1995 Mar;82(3):489-92 [7861230.001]
  • [Cites] Pediatr Neurosurg. 1996 Aug;25(2):100-4 [9075254.001]
  • [Cites] Cancer. 1999 Sep 1;86(5):858-65 [10463986.001]
  • [Cites] Neurosurgery. 1986 Jul;19(1):104-7 [3748329.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):294-9 [8022439.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1584-91 [7495283.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1248-55 [9552022.001]
  • [Cites] Am J Pathol. 1991 Aug;139(2):317-25 [1867320.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Diagn Mol Pathol. 1993 Sep;2(3):147-57 [7506981.001]
  • [Cites] Pediatr Neurosurg. 1999 Dec;31(6):307-15 [10702731.001]
  • (PMID = 11508817.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


17. Timmermann B, Schuck A, Niggli F, Weiss M, Lomax AJ, Pedroni E, Coray A, Jermann M, Rutz HP, Goitein G: Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys; 2007 Feb 1;67(2):497-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute.
  • PURPOSE: Radiotherapy plays a major role in the treatment strategy of childhood sarcomas.
  • Consequences of treatment are likely to affect the survivor's quality of life significantly.
  • We investigated the feasibility of spot-scanning proton therapy (PT) for soft tissue tumors in childhood.
  • METHODS AND MATERIALS: Sixteen children with soft tissue sarcomas were included.
  • Fourteen children had chemotherapy before and during PT.
  • All 16 children were treated with spot-scanning proton therapy at the Paul Scherrer Institute, and in 3 children the PT was intensity-modulated (IMPT).
  • Acute toxicity was low, with Grade 3 or 4 side effects according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) criteria occurring in the bone marrow only.
  • CONCLUSIONS: Proton therapy was feasible and well tolerated.
  • [MeSH-major] Protons / therapeutic use. Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Feasibility Studies. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / radiotherapy. Humans. Infant. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / mortality. Meningeal Neoplasms / radiotherapy. Quality of Life. Radiation Injuries / pathology. Rhabdomyosarcoma, Embryonal / drug therapy. Rhabdomyosarcoma, Embryonal / mortality. Rhabdomyosarcoma, Embryonal / radiotherapy. Spinal Neoplasms / drug therapy. Spinal Neoplasms / mortality. Spinal Neoplasms / radiotherapy. Survivors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084557.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


18. Raney RB, Meza J, Anderson JR, Fryer CJ, Donaldson SS, Breneman JC, Fitzgerald TJ, Gehan EA, Michalski JM, Ortega JA, Qualman SJ, Sandler E, Wharam MD, Wiener ES, Maurer HM, Crist WM: Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol; 2002 Jan;38(1):22-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997.
  • BACKGROUND: We reviewed 611 patients with parameningeal sarcoma entered on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-II through IV (1978-1997), to delineate treatment results and evaluate prognostic factors.
  • PROCEDURE: Primary sites were the middle ear/mastoid (N = 138), nasopharynx/nasal cavity (N = 235), paranasal sinuses (N = 132), parapharyngeal region (N = 29), and the pterygopalatine/infratemporal fossa (N = 77).
  • Treatment was initial biopsy or surgery followed by multiagent chemotherapy and radiation therapy (XRT).
  • Beginning in 1977, patients with cranial nerve palsy, cranial base bony erosion, and/or intracranial extension at diagnosis were considered as having meningeal involvement.
  • They received triple intrathecal medications, whole brain XRT, and then spinal XRT.
  • These treatments were successively eliminated from 1980 to 1991.
  • Favorable prognostic factors were: age 1-9 years at diagnosis; primary tumor in the nasopharynx/nasal cavity, middle ear/mastoid, or parapharyngeal areas; no meningeal involvement; and non-invasive tumors (T1).
  • Thirty-five of 526 patients (6.7%) with information about presence/absence of meningeal involvement at diagnosis developed central nervous system (CNS) extension at 5-164 weeks (median, 46 weeks) after starting therapy.
  • CONCLUSIONS: Biopsy, XRT to the target volume, and systemic chemotherapy are successful treatments for the large majority of patients with localized parameningeal sarcoma.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Meningeal Neoplasms / therapy. Outcome Assessment (Health Care). Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Clinical Protocols. Combined Modality Therapy. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Infant. Infant, Newborn. Injections, Spinal. Male. Methotrexate / administration & dosage. Neoplasm Invasiveness. Prognosis. Radiation Dosage. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley‐Liss, Inc.
  • (PMID = 11835233.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Bisogno G, De Rossi C, Gamboa Y, Sotti G, Ferrari A, Dallorso S, Donfrancesco A, Cecchetto G, Calderone M, Gandola L, Rosolen A, Carli M: Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Jun;50(6):1154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP soft tissue sarcoma committee.
  • BACKGROUND: Parameningeal rhabdomyosarcoma (PM-RMS) is a rare, highly malignant pediatric tumor arising from locations adjacent to the meninges, from where it can spread intracranially.
  • PROCEDURE: We reviewed 109 children with non-metastatic PM-RMS enrolled in the Italian RMS79, RMS88 and RMS96 protocols over a 24-year period.
  • All patients received intensive chemotherapy and standard or hyperfractionated and accelerated radiotherapy.
  • RESULTS: Five-year overall survival rose from 40% in the RMS79 to 72% in the RMS88 and RMS96 protocols (P = 0.01), where more intensive chemotherapy and hyperfractionated accelerated radiotherapy (HART) was used.
  • Delayed surgery after initial treatment was statistically associated with a better prognosis.
  • CONCLUSION: Outcome in PM-RMS patients enrolled in three consecutive Italian protocols has progressively improved, as a result of intensive chemotherapy, delayed surgery and, possibly, HART, though improved imaging and radiotherapeutic tools may have had a role as well.
  • [MeSH-major] Meningeal Neoplasms / mortality. Rhabdomyosarcoma / mortality
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Humans. Infant. Male. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18300319.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Takahashi T, Tsukuda H, Kimura H, Yoshimoto M, Tsujisaki M: Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8. Intern Med; 2010;49(5):447-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8.
  • A 57-year-old man was diagnosed as having acute monoblastic leukemia with t(9;11)(p22;q23) and trisomy 8.
  • Ten months after achieving complete response (CR) with chemotherapy, masses developed in his left forearm and in the back of his thigh, preceded by enigmatic peripheral neurological symptoms.
  • Bone marrow or meningeal relapse was not observed.
  • To our knowledge, this is the first case report of clonal evolution associated with the development of myeloid sarcoma as a relapse in AML.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / genetics. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / genetics. Trisomy / genetics
  • [MeSH-minor] Chromosome Aberrations. Drug Therapy. Forearm. Humans. Male. Middle Aged. Recurrence. Thigh

  • Genetic Alliance. consumer health - Chromosome 9, Trisomy.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190481.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement